TuHURA Biosciences (NASDAQ:HURA) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of TuHURA Biosciences (NASDAQ:HURA) from a hold rating to a sell rating in a research note released on Saturday.

Several other brokerages have also recently weighed in on HURA. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of TuHURA Biosciences in a report on Tuesday, February 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Tuesday, April 21st. Finally, Rodman & Renshaw began coverage on TuHURA Biosciences in a report on Wednesday, April 15th. They issued a “buy” rating for the company. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

TuHURA Biosciences Trading Down 5.5%

NASDAQ:HURA opened at $2.22 on Friday. The stock has a market cap of $141.15 million, a P/E ratio of -3.52 and a beta of -0.32. The stock has a 50 day simple moving average of $1.92 and a 200 day simple moving average of $1.61. TuHURA Biosciences has a 1-year low of $0.41 and a 1-year high of $4.20.

TuHURA Biosciences (NASDAQ:HURA) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). As a group, sell-side analysts forecast that TuHURA Biosciences will post -0.45 EPS for the current year.

Hedge Funds Weigh In On TuHURA Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of TuHURA Biosciences by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,269,666 shares of the company’s stock valued at $5,629,000 after purchasing an additional 35,426 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of TuHURA Biosciences by 6.4% in the 4th quarter. Geode Capital Management LLC now owns 662,481 shares of the company’s stock valued at $501,000 after purchasing an additional 39,710 shares during the last quarter. State Street Corp increased its stake in shares of TuHURA Biosciences by 4.9% in the 4th quarter. State Street Corp now owns 289,133 shares of the company’s stock valued at $219,000 after purchasing an additional 13,594 shares during the last quarter. Apollon Wealth Management LLC increased its stake in shares of TuHURA Biosciences by 17.7% in the 1st quarter. Apollon Wealth Management LLC now owns 158,010 shares of the company’s stock valued at $283,000 after purchasing an additional 23,717 shares during the last quarter. Finally, Deutsche Bank AG increased its stake in shares of TuHURA Biosciences by 209.8% in the 4th quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock valued at $61,000 after purchasing an additional 54,051 shares during the last quarter. Institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.